Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ryan Simpson
Observed name:
Simpson, Ryan
Institution:
Analysis Group (United States)
Observed institution:
Analysis Group (United States)
OpenAlex ID:
A5057210334
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM
2024
·
Lucia Masarova
, Srdan Verstovsek
, et al.
·
Future Oncology
·
21
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis
2025
·
Lucia Masarova
, Srdan Verstovsek
, et al.
·
Future Oncology
·
9
Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival
2026
·
Andrew T. Kuykendall
, Francesca Palandri
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
3
Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).
2023
·
Lucia Masarova
, Srdan Verstovsek
, et al.
·
Journal of Clinical Oncology
·
3
MPN-539 Retrospective Real-World Analysis of Baseline Characteristics, Treatment Patterns, and Survival in Patients With Myelofibrosis and Anemia Receiving Ruxolitinib
2024
·
Andrew T. Kuykendall
, Mirko Fillbrunn
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Retrospective Real-World Analysis of Baseline Characteristics and Posttreatment Hematologic Outcomes in Patients with Myelofibrosis Receiving Ruxolitinib
2023
·
Andrew T. Kuykendall
, Mirko Fillbrunn
, et al.
·
Blood
·
1
PDF
Pb2183: Transfusion-related Cost Offsets and Time Burden in Patients With Myelofibrosis (mf) Treated With Momelotinib (mmb) Vs Danazol (dan)
2023
·
Lucia Masarova
, Srdan Verstovsek
, et al.
·
HemaSphere
·
1
P1062: Indirect Treatment Comparison of Momelotinib Vs Fedratinib Safety in Patients With Myelofibrosis
2023
·
Francesca Palandri
, Lucia Masarova
, et al.
·
HemaSphere
·
1
Real-World Characteristics and Outcomes of Patients with Relapsed or Refractory Multiple Myeloma Treated with Talquetamab: Early Results from eMMpower Consortium
2025
·
Jack Khouri
, Rafael Fonseca
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Retrospective Real-World Analysis of Baseline Characteristics, Treatment Patterns, and Survival in Patients With Myelofibrosis and Anemia Receiving Ruxolitinib
2024
·
Andrew T. Kuykendall
, Mirko Fillbrunn
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MPN-091 Indirect Treatment Comparison of Momelotinib vs Fedratinib Safety in Patients With Myelofibrosis
2023
·
Lucia Masarova
, Francesca Palandri
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MPN-091 Indirect Treatment Comparison of Momelotinib vs Fedratinib Safety in Patients With Myelofibrosis
2023
·
Lucia Masarova
, Francesca Palandri
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
14
Citation count:
40
H-index:
3
I10-index:
1
Year
Topic
Type